3.61
-4.1(-53.18%)
Currency In USD
| Previous Close | 7.71 |
| Open | 2.98 |
| Day High | 7.19 |
| Day Low | 2.81 |
| 52-Week High | 11.16 |
| 52-Week Low | 2.91 |
| Volume | 85M |
| Average Volume | 2.9M |
| Market Cap | 292.8M |
| PE | -2.87 |
| EPS | -1.26 |
| Moving Average 50 Days | 5.72 |
| Moving Average 200 Days | 6.57 |
| Change | -4.1 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $26.15 as of June 26, 2025 at a share price of $3.483. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $328.61 as of June 26, 2025 at a share price of $3.483.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
GlobeNewswire Inc.
Yesterday at 11:12 PM GMT
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeut
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
GlobeNewswire Inc.
Jun 13, 2025 11:30 AM GMT
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presenta
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewswire Inc.
May 19, 2025 11:30 AM GMT
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrol